SCHEDULE: IceCure Medical: Major Shareholder Director Resigns

A significant shareholder's director, Mr. Li Haixiang, has resigned from the board of IceCure Medical Ltd., while the reporting persons maintain a 45.8% beneficial ownership stake.

Summary

• Mr. Li Haixiang, a director of Epoch Partner Investments Limited, resigned from IceCure Medical Ltd.'s board of directors on March 17, 2026.
• Epoch Partner Investments Limited and Mr. Li Haixiang (the Reporting Persons) beneficially own an aggregate of 35,846,597 Ordinary Shares of IceCure Medical Ltd.
• This ownership represents approximately 45.8% of the Issuer's outstanding Ordinary Shares, based on 73,122,293 shares outstanding as of December 31, 2025.
• The Reporting Persons hold shared voting and dispositive power over these shares.
• No transactions in the Issuer's Ordinary Shares have been effected by the Reporting Persons in the past 60 days.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral update. While a director's resignation from a major shareholder can be a point of interest, the filing provides no specific reason or further context to suggest a positive or negative impact on the company's operations or strategy. The significant ownership stake remains unchanged.

Positives

• The significant beneficial ownership (45.8%) by Epoch Partner Investments Limited and Mr. Li Haixiang indicates a strong, concentrated interest in the company's performance.

Negatives

• The resignation of a director representing a major shareholder could signal a potential shift in governance influence or strategic alignment, though the filing does not provide a reason for the resignation.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

StockSavvy.ai notes that director resignations, especially from significant shareholders, are closely watched by the market as they can sometimes precede broader strategic shifts or changes in shareholder activism. However, without further context, this filing alone does not indicate a specific industry trend.

Management Changes

Corporate Governance

Legal Proceedings

• Neither of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
• Neither of the Reporting Persons have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which they were or are subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws during the last five years.

Stakeholder Impact

• Shareholders: The resignation of a director representing a major shareholder could lead to questions regarding future strategic direction or shareholder representation, but the beneficial ownership percentage remains high.
• Board of Directors: The board will have one less member, potentially requiring a new appointment or a shift in responsibilities among remaining directors.

Key Dates

Recommendation

The filing primarily reports a change in board composition and an update on beneficial ownership, without providing new financial or operational data. While the resignation of a director representing a major shareholder is notable, the absence of a stated reason or further strategic implications suggests a neutral stance. The significant ownership stake remains, indicating continued alignment of interests. Investors should hold and monitor for further developments regarding the board's future composition and any strategic shifts.

Keywords

IceCure Medical, ICECURE, Schedule 13D/A, beneficial ownership, director resignation, corporate governance, shareholder stake, Li Haixiang, Epoch Partner Investments